Brief: GRI Bio Increasing Amount Of Shares To Sell Under Sales Deal To Offering Price Of Up To $2.6 Mln
Brief: GRI Bio Regains Compliance with Nasdaq
Brief: GRI Bio Announces Closing Of $4.0 Million Public Offering
Brief: Gri Bio Announces Reverse Stock Split
Brief: Connect Biopharma Announces New Leadership And Chair Of The Board Of Directors
Brief: GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Brief: GRI Bio Files For Mixed Shelf Offering Of Up To $75 Mln
Brief: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
Brief: GRI Bio Receives MHRA Authorization To Conduct Phase 2a Biomarker Study Evaluating GRI-0621 In the UK
Brief: GRI Bio Announces Pricing Of $5.5 Million Public Offering
Brief: Gri Bio Approved A 1-For-7 Reverse Stock Split Of Company's Common Stock
Brief: GRI Bio Says Interim Data From Phase 2a Biomarker Study Is Expected In First Half Of 2024
Brief: GRI Bio Announces FDA Clearance Of IND For Lead Program GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis
Brief: GRI Bio Partners with Respiratory Translational Research Collaboration to Advance NKT Regulation Technology
Brief: Gri Bio Files For Offering Of 4.1 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Gri Bio Enters Into Asset Purchase Agreement With Aardvark Therapeutics, Inc. For The Sale Of Legacy Asset, Adair
Brief: GRI Bio Inc Expects To Commence Phase 1A/B SLE Study In 1H 2024 With Topline Results Expected 2H 2024
Brief: GRI Bio Bolsters Patent Portfolio
Brief: GRI Bio Announces Corporate Rebranding And Launch Of New Website